Bristol-Myers Squibb (BMY) Earns Daily News Sentiment Rating of 0.21
News articles about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.6769806155243 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- A Look at Bristol-Myers Squibb’s Revenue in 3Q17 (finance.yahoo.com)
- How Bristol-Myers Squibb’s Oncology Portfolio Performed in 3Q17 (finance.yahoo.com)
- Opdivo: Blockbuster Oncology Drug in 3Q17 (finance.yahoo.com)
- BRIEF-Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists (reuters.com)
- U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review (finance.yahoo.com)
Bristol-Myers Squibb (NYSE BMY) traded up $0.19 during trading hours on Thursday, reaching $63.47. The company had a trading volume of 4,352,400 shares, compared to its average volume of 8,361,882. The company has a market cap of $103,570.38, a P/E ratio of 21.38, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is 61.42%.
A number of brokerages have recently issued reports on BMY. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday. Jefferies Group reiterated a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target for the company. in a research report on Thursday, September 28th. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $64.93.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
WARNING: “Bristol-Myers Squibb (BMY) Earns Daily News Sentiment Rating of 0.21” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-bmy-earns-daily-news-sentiment-rating-of-0-21/1764268.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.